Drug Profile

Research programme: leishmaniasis therapeutics - AbbVie/Drugs for Neglected Diseases Initiative

Alternative Names: DNDI-6588; DNDI-6749; Leishmaniasis L205 series

Latest Information Update: 13 Mar 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Mar 2020 No development reported - Preclinical for Visceral leishmaniasis in USA (Drugs for Neglected Diseases Initiative pipeline, March 2020)
01 Feb 2019 Preclinical trials in Visceral leishmaniasis in USA (Drugs for Neglected Diseases Initiative website, February 2019)
30 Jan 2012 Abbott and Drugs for Neglected Diseases Initiative enter into a research agreement for the development of therapies for the treatment of tropical diseases, including leishmaniasis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com